Endologix Adds Jane E. Kiernan to its Board of Directors
March 17 2020 - 6:30PM
Business Wire
Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a
developer and marketer of innovative treatments for aortic
disorders, today announced that it has appointed Jane E. Kiernan to
its board of directors, effective March 12, 2020. Ms. Kiernan has
also been appointed to serve on the Audit Committee and the
Nominating, Governance and Compliance Committee.
“We are thrilled to add an executive of Jane’s caliber to our
board,” commented Dan Lemaitre, Chairman of the Endologix board of
directors. “I’m confident that Jane’s extensive industry experience
will be a key asset as we continue to pursue our long-term growth
strategy.”
“Jane’s 30 years of financial and operational expertise in the
healthcare sector will be instrumental as we take Endologix to the
next stage of growth,” said John Onopchenko, Chief Executive
Officer of Endologix, Inc. “The strategic insight Jane has gained
through a wealth of executive and board experience will be
invaluable for Endologix as we continue to drive innovation in the
abdominal aortic aneurysms (“AAA”) market.”
Ms. Kiernan has served on the board of directors of Axonics
Modulation Technologies, Inc. since 2019 and currently serves on
its audit committee. In 2017, she co-founded K2 Biotechnology
Ventures, an investment firm engaged in developing and
commercializing portfolios of university and medical center
innovations in partnership with venture capital, healthcare
corporations, and philanthropic healthcare foundation partners. She
previously served on the board of directors of American Medical
Systems from 2006 through 2011, when it was acquired by Endo
Pharmaceuticals.
During her distinguished career, Ms. Kiernan served as Chief
Executive Officer and board member of Salter Labs from 2010 to
2017, over which time she and the team developed and executed a
strategy to double the size of the company. Prior to joining Salter
Labs, she spent nine years at Baxter Healthcare Corporation
(“Baxter”) in executive and general management roles of increasing
responsibility, eventually responsible for a $1.5 billion global
parenteral nutrition and IV fluid therapy business. Prior to
Baxter, Ms. Kiernan served as Vice President of Finance,
Distribution and Services at Allegiance Healthcare Corporation,
where she co-led the successful turnaround of a $4 billion
distribution business.
“I am very excited to be joining Endologix at such a pivotal
time in the Company’s history,” commented Ms. Kiernan. “I look
forward to working closely with the members of the Endologix board
and leadership team as we revitalize the business and seek
opportunities to drive stockholder value through innovation and
improved patient outcomes.”
Ms. Kiernan received her Bachelor of Business Administration
from Southern Methodist University in Dallas, Texas.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of AAA. AAA is a
weakening of the wall of the aorta, the largest artery in the body,
resulting in a balloon-like enlargement. Once an AAA develops, it
continues to enlarge and, if left untreated, becomes increasingly
susceptible to rupture. The overall patient mortality rate for
ruptured AAA is approximately 80%, making it a leading cause of
death in the U.S. For more information, visit www.endologix.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200317005847/en/
Endologix, Inc. Vaseem Mahboob, CFO (949) 595-7200
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2023 to Sep 2024